The Annual General Meeting in Bactiguard Holding AB (publ) will be held on Thursday 21 May, 2015 in Stockholm. At the Annual General Meeting (AGM) in 2014, it was resolved that the Nomination Committee in Bactiguard Holding AB (publ) shall be formed in a process where the Chairman of the Board contacts the three largest shareholders, based on...
Third quarter (July-September 2014) Revenues amounted to SEK 28.1 (32.5) million, a decrease of 14 % over the corresponding quarter last year EBITDA amounted to SEK 2.2 (4.7) million, a decrease of 53 % over the corresponding quarter last year Reported net profit for the quarter amounted to SEK -15.7 (-5.1) million, corresponding to SEK -0.47...
Bactiguard Holding AB publishes the interim report for the third quarter on Friday 14 November at 08:00 CET In connection with this, a conference call for analysts and media will be held at 10:00 CEO on November 14. CEO Johan Rugfelt and CFO Fredrik Järrsten will present the interim report and answer questions. The report will be available at...
Bactiguard strengthens its sales and marketing organization by recruiting Nina Nilsson as Head of Marketing. In addition to marketing, she will also focus on developing the Swedish market. Bactiguard is in a rapid expansion phase. Building strong marketing and sales capabilities to support our distributors across the world and develop direct...
Bactiguard establishes market presence in Portugal by entering an exclusive distribution agreement with Socime Medical Ltd, covering all products in the Bactiguard infection protection portfolio. Expanding our geographical footprint in Europe is an important part of Bactiguard’s strategy. By entering the Portuguese market we take an important...
Second quarter (April-June 2014) Revenues amounted to SEK 31.2 (22.1) million, an increase of 41% over the corresponding period last year EBITDA, excluding costs related to the IPO, amounted to SEK 5.2 (3.8) million, an increase of 36% Net profit for the quarter amounted to SEK -44.1 (-13.8) million, corresponding to SEK -2.04 (-0.69) per share,...
Bactiguard Holding AB publishes the interim report for the second quarter 2014 on August 15 at 08:00 CET. In connection with this, a telephone conference for analysts and media will be held at 10:00 CET on August 15. CEO Johan Rugfelt and CFO Fredrik Järrsten will present the interim report and answer questions. The report will be available at...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. Swedbank AB (publ) (”Swedbank”) has exercised the possibility to, in connection with the initial public offering (“IPO”) of Bactiguard Holding AB (publ) (“Bactiguard” or the”Company”), exercise price stabilization...
Bactiguard is expanding its business, with focus on Europe, the Middle East, Asia, South America and Southern Africa. The recruitment of Erik Düring as Regional Sales Director Europe is an important step in strengthening the sales and marketing organization, which supports the company’s distributors and develops the markets where Bactiguard...
Bactiguard establishes market presence in Southern Africa and has entered into exclusive distribution agreements, covering seven sub-Saharan countries and Bactiguard’s complete portfolio of solutions for infection control. An initial order for Foley catheters has already been shipped to Zambia. The order is for Foley catheters, primarily...
Bactiguard's proven and patented technology is the company's most important asset. Following articles in the Swedish newspaper Svenska Dagbladet, Bactiguard wishes to clarify some important facts. An article was today published in Svenska Dagbladet newspaper featuring Bactiguard's technology. Since the article does not give a fair picture, the...
In June 2014 the number of shares and votes in Bactiguard has increased by 12,786,373 Class B shares and the same number of votes. As earlier announced, the change in the number of shares and votes is a result of the new issues made in relation to the offer to acquire Class B shares in Bactiguard in connection with the listing of the company's...
A recently published clinical study* from the United States, concludes that Bactiguard coated Foley catheters significantly reduce symptomatic catheter associated urinary tract infections (CAUTI) and use of antibiotics. A 47-58 percent reduction of CAUTI and a 60 percent relative reduction of antibiotic use were recorded. This non-randomized...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. Bactiguard Holding AB (publ) (“Bactiguard” or “The Company”) hereby announces the outcome of the offer to acquire shares in Bactiguard and listing on NASDAQ OMX Stockholm (“the Offer”). Interest in the Offer has been...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. The board of directors of Bactiguard Holding AB (publ) (“Bactiguard” or ”the Company”) and the Company’s principal owners, Thomas von Koch through Bactiguard B.V. and Christian Kinch through KK Invest AB, (”Principal...
At an expert panel session on 4 June 2014, the Chinese Center for Medical Device Evaluation (CMDE) informed that it will approve Bactiguard’s BIP Foley catheters. This is a major step en route towards final regulatory approval and commencement of sales in mainland China.The most important step in achieving regulatory approval for...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. The information regarding the total nominal amount of bonds set-off for shares, which was communicated by Bactiguard Holding AB (publ) (“Bactiguard” or ”the Company”) through press release titled “Set-off issue for...
Professor Kenneth Chien becomes Scientific Advisor to Bactiguard and will also lead the company’s Scientific Board. Professor Chien is an internationally recognized leader and pioneer in cardiovascular science. In 2013, he was recruited to Karolinska Institutet from Harvard University, USA. "Hospital Acquired infections are an increasing...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. On 23 May, 2014 Bactiguard Holding AB (publ) (“Bactiguard” or ”the Company”) announced that holders of the Company’s bonds would be offered* the option to offset their bonds against Bactiguard shares....
Bactiguard’s BIP Foley Catheters in latex and silicone have been approved for new patient groups. The approval* includes patients who need suprapubic catheterization and long term usage. “Bactiguard’s growth strategy includes adding new devices and new applications to our product portfolio. The approval of our BIP Foley Catheters...
Bactiguard and MAQUET Critical Care AB (MAQUET), a division of the Getinge Group, enter a collaboration to develop Bactiguard®-coated catheters for patients in intensive care.Bactiguard’s strategy includes expanding its licensing business. MAQUET’s intention is to expand its portfolio of advanced monitoring solutions. Therefore,...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. In a press release issued today, the Board of Directors of Bactiguard Holding AB (publ) (“Bactiguard” or “the Company”) confirmed its intention to proceed with an IPO of Bactiguard on NASDAQ OMX Stockholm....
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. The Board of Directors of Bactiguard Holding AB (publ) (“Bactiguard”) confirms its intention to proceed with an IPO of Bactiguard on NASDAQ OMX Stockholm. Subject to necessary decisions being taken, receipt of NASDAQ OMX...
Bactiguard has signed an exclusive distribution agreement with Promedon, which allows the company to sell Bactiguard’s complete portfolio of medical devices in Argentina, Brazil, Chile and Mexico. Through this partnership, Bactiguard expands its market presence to 41 countries worldwide. Swedish medtech company Bactiguard has entered into an...
Swedish medical device company Bactiguard has signed Azaris Medical Equipment LLC in Ukraine to represent the company. Azaris Medical Equipment will be introducing Bactiguard’s complete portfolio for infection control, including urinary, intravenous and respiratory catheters. Bactiguard is present in over 35 countries worldwide and recently...
Swedish medical device company Bactiguard has been exhibiting at the health care exhibition Arab Health in Dubai since 2008. This year will be the 7th time the company is present at the exhibition. Arab Health plays a crucial role for not just health care in the Middle East-region, but also in a global perspective and makes an excellent arena for...
Swedish medtech company Bactiguard has signed Acucare Systems in Malaysia to represent the company in the Malaysian market. Acucare Systems will now be introducing Bactiguard’s complete portfolio for infection control, including urinary, intravenous and respiratory catheters. A few months ago Bactiguard proudly announced that they signed...